Wegovy vs. Mounjaro: Which Weight-Loss Injection Is Right For You?

If you are considering this kind of weight-loss treatment, you have probably come across two of the most widely discussed options: Wegovy and Mounjaro. These prescription medicines are designed to help eligible adults manage obesity. They are meant to work simultaneously with a reduced calorie intake and increased physical activity.

The similarities between these two medications are clear. However, differences also exist. Although Mounjaro and Wegovy are both given as once-weekly injections, they contain different active ingredients and function through different hormonal pathways.

When making a choice, it is important to understand that weight-loss treatment involves more than numbers on the scale. In this article, we explain the effectiveness, dosing, tolerability, NHS access and suitability of Wegovy and Mounjaro.

What's the difference between Wegovy and Mounjaro?

The main difference is the active ingredient. Wegovy contains semaglutide, a GLP-1 receptor agonist, while Mounjaro contains tirzepatide, a dual (GIP and GLP-1) receptor agonist. This means it acts on two hormonal pathways involved in appetite, glucose regulation, and metabolism.

Both Mounjaro and Wegovy are considered similar treatments as both are injectable medications administered once a week. Both can substantially reduce and regulate appetite and food intake, and improve blood sugar regulation when used along with lifestyle changes. However, their pharmacology is not identical.

Feature	Wegovy	Mounjaro
Active ingredient	Semaglutide	Tirzepatide
Mechanism	GLP-1 receptor agonist	GIP + GLP-1 receptor agonist
Administration	Once-a-week injection with a pre-filled pen	Once-a-week injection with a pre-filled pen
Standard Maintenance	2.4 mg weekly	5, 10, or 15 mg weekly
Maximum Dose	7.2 mg for eligible adults with obesity, where indicated	15 mg weekly
Main Effects	Appetite reduction, satiety, glucose regulation	Appetite reduction, satiety, glucose regulation
Common Side Effects	Nausea, diarrhoea, vomiting, constipation	Nausea, diarrhoea, vomiting, constipation

Mounjaro or Wegovy: key differences

Both medicines act on receptors involved in appetite and glucose regulation. Semaglutide activates GLP-1 receptors, while tirzepatide activates both GIP and GLP-1 receptors. These effects can increase satiety, reduce hunger and lower food intake.

Another positive effect is on the way the body handles glucose. This is particularly important for people with insulin resistance or type 2 diabetes.

The difference is that Wegovy primarily targets the GLP-1 pathway, whereas Mounjaro's active ingredient tirzepatide targets both GLP-1 and GIP. Here’s a more detailed overview:

Wegovy and the GLP-1 pathway to lose weight

Semaglutide (the active ingredient in Wegovy) activates GLP-1 receptors [1].

GLP-1 is a hormone released in response to food. It acts on the brain, pancreas and gastrointestinal tract [2]. By activating GLP-1 receptors, semaglutide increases feelings of fullness and reduces appetite.

Semaglutide primarily supports weight loss by acting on appetite-regulating pathways in the brain, increasing satiety and reducing hunger and energy intake. [3]

Semaglutide also helps the body release insulin and reduces inappropriate glucagon secretion, resulting in improved blood sugar control (particularly in people with type 2 diabetes) [4].

All of this together makes a reduced-calorie diet easier to maintain and supports weight loss over time.

Mounjaro's dual GLP-1 and GIP mechanism

Mounjaro's active ingredient is tirzepatide. It activates both GLP-1 and GIP receptors [5].

Glucose-dependent insulinotropic polypeptide (GIP) is a hormone involved in nutrient sensing and insulin secretion [6]. So, rather than acting through GLP-1 alone, Mounjaro has a dual-hormone mechanism [7].

This dual agonism affects appetite regulation and glucose-dependent insulin secretion, but the greater average weight loss seen with tirzepatide should not be attributed to one simple mechanism alone.

Tirzepatide’s insulinotropic effect is linked to elevated glucose levels [8]. This means Mounjaro helps the body release insulin when glucose levels rise.

Mounjaro vs Wegovy: how do the clinical results compare?

Mounjaro has garnered significant interest due to this two-pathway approach. Additionally, in comparative research, tirzepatide has produced greater average reductions in body weight than semaglutide [9].

However, some people respond particularly well to semaglutide, while others may experience a stronger response to tirzepatide [10]. Multiple factors influence this, including tolerability, adherence, starting weight, diet, physical activity, genetics, and general health.

Therefore, the fact that Mounjaro vs Wegovy trials favour tirzepatide on average does not mean Mounjaro is automatically the right choice for every patient.

Is Mounjaro really more effective than Wegovy?

Here’s what head-to-head research results tell us:

In the SURMOUNT-5 trial, 751 adults with obesity or overweight without diabetes were randomly assigned to tirzepatide or semaglutide. At 72 weeks, average body weight decreased by approximately 20.2% with tirzepatide compared with 13.7% with semaglutide. Participants receiving tirzepatide were also more likely to achieve reductions of at least 10%, 15%, 20% and 25%. Gastrointestinal side effects were the most common adverse events in both groups and were generally mild to moderate [9, 11].

So, on average, more weight loss was achieved with tirzepatide in this head-to-head study. However, “more effective” does not necessarily mean “better for everyone.”

For example, someone may have a strong response to Wegovy, tolerate it very well, and have cardiovascular considerations that make semaglutide particularly relevant. For adults with established heart disease and overweight or obesity, semaglutide also has evidence and a UK indication for reducing the risk of major adverse cardiovascular events.

Another person may prioritise achieving greater weight loss and may be a good candidate for tirzepatide.

Dose escalation for Mounjaro and Wegovy: how long before you reach full strength?

Both Wegovy and Mounjaro start at relatively low doses. The main reason is to allow the gastrointestinal system to adapt and reduce the risk of uncomfortable side effects. Hence, the starting dose is not the same as the therapeutic maintenance dose [12]. Dose escalation is gradual, and patients do not necessarily need to reach the highest possible dose.

How quickly does Wegovy reach full strength?

Wegovy traditionally starts at 0.25 mg once weekly towards the highest dose of 2.40 mg.

The usual escalation is:

Weeks	Weekly dose
1 to 4	0.25 mg
5 to 8	0.50 mg
9 to 12	1.00 mg
13 to 16	1.70 mg
17 and on	2.40 mg

The product information in the UK now allows an increase to 7.2 mg once weekly, where needed, after at least four weeks at 2.4 mg. This higher dose is authorised only for adults with obesity (a BMI of 30 or above); it does not apply to people with a BMI below 30 taking Wegovy for weight management, nor to those taking it to reduce cardiovascular risk.

How quickly does Mounjaro reach full strength?

Mounjaro starts at 2.5 mg once weekly. The dose is increased to 5 mg weekly after four weeks. When further weight loss or glucose control is required, the dose may be increased in 2.5 mg increments (with four weeks at each dose) to a highest maintenance dose of 15 mg weekly [13].

Tolerability: which is easier to stick with?

Tolerability is individual and varies considerably between patients. So, there is no universal winner when comparing Mounjaro and Wegovy. Both treatments commonly cause gastrointestinal symptoms, especially during dose escalation. These digestive symptoms tend to diminish as the body adjusts to the medicine [14].

What are some common gastrointestinal side effects in the first few months?

The most frequently reported effects include:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Abdominal discomfort or stomach pain

Both semaglutide 2.4 mg and tirzepatide have a similar gastrointestinal profile. Nausea, diarrhoea, vomiting and constipation are among the most frequently reported adverse effects in clinical studies. Most of these are mild to moderate and usually occur during dose escalation.

Serious but rare side effects of Wegovy and Mounjaro

Most patients tolerate both medicines well. Still, there are several rare but clinically significant risks that anyone starting treatment should be aware of [15, 16].

Pancreatitis. Both medicines have been associated with acute pancreatitis in post-marketing surveillance. Symptoms — severe, persistent abdominal pain radiating to the back, often accompanied by nausea and vomiting — warrant immediate medical attention and discontinuation of the medication. Men and women with a personal or family history of pancreatitis should discuss this risk with their prescriber before starting.

Gallbladder problems. Rapid weight loss of any cause increases the risk of gallstone formation, and GLP-1 agonists appear to compound this through direct effects on gallbladder motility. Clinical trials for both semaglutide and tirzepatide reported higher rates of cholelithiasis and cholecystitis compared to placebo.

Thyroid C-cell tumours. In rodent studies, semaglutide and tirzepatide caused dose-dependent thyroid C-cell tumours. Whether this risk translates to humans remains uncertain. In the United States both products are formally contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), but the UK and EU product information treats this history as a precaution rather than a formal contraindication – the only listed contraindication for either medicine here is hypersensitivity. Anyone with such a history should still raise it with their prescriber before starting.

Diabetic retinopathy complications. In patients with pre-existing type 2 diabetes and diabetic retinopathy, rapid improvements in glycaemic control — as seen with semaglutide — have been associated with a temporary worsening of retinopathy. This is a known phenomenon with any fast-acting glucose-lowering treatment and should be monitored in at-risk patients.

Acute kidney injury. Severe nausea, vomiting, and diarrhoea can cause significant dehydration, which in vulnerable patients may precipitate acute kidney injury. This is an indirect effect rather than a direct nephrotoxic one, but it is clinically relevant for patients with existing renal impairment. Pulmonary aspiration under anaesthesia. Because both medicines slow gastric emptying, the stomach may still contain food after the usual pre-operative fasting, and cases of stomach contents being inhaled into the lungs during general anaesthesia or deep sedation have been reported. The MHRA advises telling the surgical team and anaesthetist about treatment well before any planned procedure.

Suicidal ideation. The European Medicines Agency and MHRA have reviewed signals around suicidal thoughts in patients taking GLP-1 receptor agonists. Current evidence does not establish a causal link, but both regulatory bodies continue to monitor the data, and patients experiencing mood changes or thoughts of self-harm should seek medical advice promptly. [22]

Mounjaro and the contraceptive pill

Tirzepatide can temporarily reduce exposure to oral contraception, particularly after starting treatment and after dose increases [17].

For women with overweight or obesity who use an oral contraceptive, the UK product information advises switching to a non-oral contraceptive method or adding a barrier method for four weeks after starting tirzepatide and for four weeks after each dose increase.

Mounjaro vs Wegovy: long-term tolerability data

Wegovy and Mounjaro are both relatively modern weight loss medications. This means that long-term evidence is still evolving, although significant clinical trial experience exists.

Both medicines are licensed to be used alongside reduced-calorie dietary measures and increased physical activity. Longer-term studies continue to clarify durability of benefit and safety over extended treatment.

Wegovy and heart health

One important distinction when comparing Wegovy and Mounjaro is the cardiovascular evidence.

The outcomes of the SELECT cardiovascular trial show that adults with established cardiovascular disease and obesity who received semaglutide 2.4 mg had fewer major adverse cardiovascular events than those receiving placebo [18].

The primary composite outcome occurred in 6.5% of semaglutide-treated participants compared with 8.0% of placebo-treated participants, corresponding to a hazard ratio of 0.80.

NHS availability: which can you get on prescription?

You can get Wegovy and Mounjaro online through regulated private online doctor services and digital pharmacies. Both are prescription weight loss medications, but access through the NHS is considerably more restricted than private prescribing.

Wegovy on the NHS

To buy Wegovy in the UK, the medication has to be prescribed by a specialist. Eligible people, through the NHS, are those whose weight is associated with health problems.

NHS guidance includes body mass index (BMI) thresholds and weight-related medical conditions when determining eligibility [19]. For example, semaglutide may be considered for people with a BMI of 35 or above with relevant health problems, with lower BMI thresholds applying to certain ethnic groups.

Since May 2026, NICE also recommends semaglutide up to 2.4 mg weekly to reduce major cardiovascular events in adults with established cardiovascular disease and BMI ≥27 kg/m², within its marketing authorisation.

Mounjaro on the NHS

Mounjaro is also available through NHS pathways for eligible people.

NICE recommends tirzepatide for adults with an initial BMI of at least 35 kg/m² and at least one weight-related comorbidity, alongside diet and physical activity [20]. It is important to check eligibility locally. For example, NHS England's phased criteria include conditions such as:

• Type 2 diabetes
• Cardiovascular disease
• Obstructive sleep apnoea
• Dyslipidaemia
• High blood pressure

Price and value: comparing the cost of Mounjaro vs Wegovy in the UK

Private prices for weight-loss injections vary depending on the provider, dose, consultation fees and follow-up arrangements.

Mounjaro's NHS list prices vary by dose, ranging from £133 for a four-week 2.5 mg supply to £330 for 12.5 mg or 15 mg, excluding VAT, although NHS commercial arrangements differ from these list prices.

NICE's 2026 information lists Wegovy at £73.25 for 0.25/0.5/1 mg, £124.53 for 1.7 mg, and £175.80 for 2.4 mg, excluding VAT, though confidential NHS discounts apply.

Private pricing should be viewed as part of the complete treatment plan, not the price of one pen. Prices for Wegovy on reputable online platforms range from £95 to £215, while Mounjaro would cost around £140 to £280.

Finding the right fit: who should take which?

Choosing between Wegovy vs Mounjaro is an individual clinical decision. Neither medicine should be used in pregnancy or while breastfeeding, and both need to be stopped in advance of trying to conceive – about two months beforehand for semaglutide, which stays in the body longer, and about one month for tirzepatide. Anyone planning a pregnancy should factor this into the choice and timing of treatment. The factors that should influence the choice include:

• Your BMI
• Medical history
• Cardiovascular risk
• Diabetes status
• Current medicines
• Previous treatment response
• Eating patterns
• Tolerance of gastrointestinal symptoms

When Wegovy may be the better choice?

Wegovy may be appropriate when semaglutide's GLP-1 mechanism and evidence base fit the patient's needs. It may also be particularly relevant for people with established cardiovascular disease. Additionally, it may be a sensible option for someone who has previously responded well to semaglutide or who prefers its dosing pathway.

When Mounjaro may be the better choice?

Mounjaro’s dual GIP/GLP-1 activity and results in comparative research make tirzepatide one of the most effective weight-loss treatments currently available. Therefore, Mounjaro may be a better choice for individuals looking for a greater average weight loss.

Which one is better for type 2 diabetes?

Both medicines can improve blood sugar. However, treatment decisions become more complex when other diabetes medications are involved.

Mounjaro is licensed for treating type 2 diabetes as well as for weight management. Wegovy is licensed for weight management and, in eligible adults, cardiovascular risk reduction; semaglutide products used specifically for type 2 diabetes have separate indications and dosing. If diabetes treatment is the primary goal, the choice should be based on the relevant diabetes indication and guideline rather than simply comparing Wegovy with Mounjaro as weight-loss medicines.

Is it possible to switch from one to the other?

Switching is possible, but the two medicines should not be used together. Wegovy should not be combined with another GLP-1 receptor agonist, and tirzepatide should not simply be added to an existing GLP-1 treatment without appropriate medical direction.

There is also no simple direct dose equivalence between semaglutide and tirzepatide. Only a specialist should determine the following:

• When to switch?

• Which dose to start with?

• How quickly to escalate?

The goal should always be to find a sustainable dose that provides meaningful weight loss with acceptable tolerability.

Which other weight loss options to consider?

Weight management should not rely only on medications. They can help, but only as a part of a comprehensive treatment plan that includes nutrition, resistance training, aerobic activity, sleep, stress management and behavioural support [21].

Other clinically approved medicines may also be appropriate depending on BMI, comorbidities, contraindications and weight loss goals.

Additionally, a well-structured weight-loss journey should include realistic targets, monitoring of body composition and metabolic health, nutritional support and a strategy for maintaining results.

Frequently Asked Questions

Can you switch from Wegovy to Mounjaro?

Yes, switching is possible when clinically appropriate. However, the timing and starting dose should be determined by a medical specialist. Never assume that the dose of one medicine directly corresponds to a dose of the other.

How long does it take to see results?

Reduced appetite comes before meaningful weight loss. Since both medicines require gradual dose escalation, the full effects may take several months.

Additionally, individual results vary considerably. Clinical trials provide average outcomes, not guaranteed results for every patient.

What happens to your weight if you stop?

Obesity is a chronic disease that requires a long-term weight management strategy. Therefore, stopping treatment can lead to weight regain. In studies of both semaglutide and tirzepatide, discontinuation was associated with regain of some previously lost weight.

Which medicine causes less nausea?

Neither can reliably be described as the medication that causes less nausea for everyone.

Nausea is common with both Mounjaro and Wegovy, particularly during dose escalation. Individual tolerability varies, and the rate of dose escalation can make an important difference.

Can you take Wegovy and Mounjaro together?

No! Wegovy and Mounjaro have overlapping effects on the GLP-1 pathway and should not be combined as a routine weight loss treatment. Always inform your doctor if you are taking any other medications for weight loss.